Mechanistic Insights into Side Effects of Troglitazone and Rosiglitazone Using a Novel Inverse Molecular Docking Protocol
- PMID: 33670968
- PMCID: PMC7997210
- DOI: 10.3390/pharmaceutics13030315
Mechanistic Insights into Side Effects of Troglitazone and Rosiglitazone Using a Novel Inverse Molecular Docking Protocol
Abstract
Thiazolidinediones form drugs that treat insulin resistance in type 2 diabetes mellitus. Troglitazone represents the first drug from this family, which was removed from use by the FDA due to its hepatotoxicity. As an alternative, rosiglitazone was developed, but it was under the careful watch of FDA for a long time due to suspicion, that it causes cardiovascular diseases, such as heart failure and stroke. We applied a novel inverse molecular docking protocol to discern the potential protein targets of both drugs. Troglitazone and rosiglitazone were docked into predicted binding sites of >67,000 protein structures from the Protein Data Bank and examined. Several new potential protein targets with successfully docked troglitazone and rosiglitazone were identified. The focus was devoted to human proteins so that existing or new potential side effects could be explained or proposed. Certain targets of troglitazone such as 3-oxo-5-beta-steroid 4-dehydrogenase, neutrophil collagenase, stromelysin-1, and VLCAD were pinpointed, which could explain its hepatoxicity, with additional ones indicating that its application could lead to the treatment/development of cancer. Results for rosiglitazone discerned its interaction with members of the matrix metalloproteinase family, which could lead to cancer and neurodegenerative disorders. The concerning cardiovascular side effects of rosiglitazone could also be explained. We firmly believe that our results deepen the mechanistic understanding of the side effects of both drugs, and potentially with further development and research maybe even help to minimize them. On the other hand, the novel inverse molecular docking protocol on the other hand carries the potential to develop into a standard tool to predict possible cross-interactions of drug candidates potentially leading to adverse side effects.
Keywords: CANDOCK; inverse molecular docking; rosiglitazone; side effects; thiazolidinediones; troglitazone.
Conflict of interest statement
The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.
Figures
![Figure 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/7997210/bin/pharmaceutics-13-00315-g001.gif)
![Figure 2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/7997210/bin/pharmaceutics-13-00315-g002.gif)
![Figure 3](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/7997210/bin/pharmaceutics-13-00315-g003.gif)
![Figure 4](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/7997210/bin/pharmaceutics-13-00315-g004.gif)
![Figure 5](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/7997210/bin/pharmaceutics-13-00315-g005.gif)
![Figure 6](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/7997210/bin/pharmaceutics-13-00315-g006.gif)
![Figure 7](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/7997210/bin/pharmaceutics-13-00315-g007.gif)
Similar articles
-
Performance of preclinical models in predicting drug-induced liver injury in humans: a systematic review.Sci Rep. 2021 Mar 18;11(1):6403. doi: 10.1038/s41598-021-85708-2. Sci Rep. 2021. PMID: 33737635 Free PMC article.
-
Lipoprotein effects of different thiazolidinediones in clinical practice.Endocr Pract. 2002 Nov-Dec;8(6):406-10. doi: 10.4158/EP.8.6.406. Endocr Pract. 2002. PMID: 15251829
-
Severe cholestatic hepatitis caused by thiazolidinediones: risks associated with substituting rosiglitazone for troglitazone.Dig Dis Sci. 2002 Jul;47(7):1632-7. doi: 10.1023/a:1015895925374. Dig Dis Sci. 2002. PMID: 12141828
-
Differentiating members of the thiazolidinedione class: a focus on safety.Diabetes Metab Res Rev. 2002 Mar-Apr;18 Suppl 2:S23-9. doi: 10.1002/dmrr.252. Diabetes Metab Res Rev. 2002. PMID: 11921435 Review.
-
Hepatotoxicity with thiazolidinediones: is it a class effect?Drug Saf. 2001;24(12):873-88. doi: 10.2165/00002018-200124120-00002. Drug Saf. 2001. PMID: 11735645 Review.
Cited by
-
Exploration of Polysaccharides from Phyllanthus emblica: Isolation, Identification, and Evaluation of Antioxidant and Anti-Glycolipid Metabolism Disorder Activities.Molecules. 2024 Apr 12;29(8):1751. doi: 10.3390/molecules29081751. Molecules. 2024. PMID: 38675571 Free PMC article.
-
Metabolites in the regulatory risk assessment of pesticides in the EU.Front Toxicol. 2023 Dec 19;5:1304885. doi: 10.3389/ftox.2023.1304885. eCollection 2023. Front Toxicol. 2023. PMID: 38188093 Free PMC article. Review.
-
MMPP promotes adipogenesis and glucose uptake via binding to the PPARγ ligand binding domain in 3T3-L1 MBX cells.Front Pharmacol. 2022 Oct 21;13:994584. doi: 10.3389/fphar.2022.994584. eCollection 2022. Front Pharmacol. 2022. PMID: 36339572 Free PMC article.
-
Peroxisome proliferator-activated receptor gamma as a therapeutic target for hepatocellular carcinoma: Experimental and clinical scenarios.World J Gastroenterol. 2022 Jul 28;28(28):3535-3554. doi: 10.3748/wjg.v28.i28.3535. World J Gastroenterol. 2022. PMID: 36161051 Free PMC article. Review.
-
Inverse Molecular Docking Elucidating the Anticarcinogenic Potential of the Hop Natural Product Xanthohumol and Its Metabolites.Foods. 2022 Apr 26;11(9):1253. doi: 10.3390/foods11091253. Foods. 2022. PMID: 35563976 Free PMC article.
References
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous